Latest News

Pliant’s stock gains 41% after sharing positive data about its fibrosis therapy candidate


Shares of Pliant Therapeutics Inc.

jumped 41.6% in premarket trading on Monday after the company shared positive data from a Phase 2a clinical trial for its experimental idiopathic pulmonary fibrosis treatment. The study, which so far has evaluated 40-, 80-, and 160-milligram doses, met the primary and secondary endpoints. Pliant said Monday it also plans to test a 320-milligram dose of the therapy in the Phase 2 trial, with plans to share 12-week data from that cohort early next year. Pliant’s stock is down 34.2% this year, while the broader S&P 500

has declined 18.2%.

If this stock market is shaping up like 2008, here’s where we could be headed next, says strategist

Previous article

Elon Musk Responds to Twitter’s Threat to Sue Him Over Reneging on Deal — With a Meme

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News